>   Structural Summary
100% seqID Fv Structure4nki [Fvs: HL], 5grj [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
Highest Clinical Trial (January '23)Approved
Estimated Status (January '23)Active
Recorded Developmental TechnologyHuman Phage Display
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedAIO Studien gGmbH, Array BioPharma, Chong Kun Dang, Dana-Farber Cancer Institute, Debiopharm, eFFECTOR Therapeutics, EMD Serono, Forty Seven, Fred Hutchinson Cancer Research Center, Gachon University Gil Medical Center, Hellenic Cooperative Oncology Group, Hospices Civils de Lyon, Johannes Gutenberg-University Mainz, M. D. Anderson Cancer Center, Merck KGaA, National Cancer Institute (USA), National Cancer Institute Slovakia, Netherlands Cancer Institute, Pfizer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Syndax Pharmaceuticals, Transgene, University College London, University of Birmingham, University of California San Diego, University of Iowa, Vaccinex, Vanderbilt-Ingram Cancer Center, VAXIMM, Verastem Oncology, Washington University School of Medicine
Conditions ApprovedMerkel cell carcinoma, Urogenital cancer, Renal cell carcinoma
Conditions ActiveBreast cancer, Diffuse large B cell lymphoma, Gastric cancer, Head and neck cancer, Non-small cell lung cancer, Ovarian cancer, Bladder cancer, Endometrial cancer, Fallopian tube cancer, Germ cell and embryonal neoplasms, Gestational trophoblastic disease, Glioblastoma, Haemangiosarcoma, Intestinal cancer, Leiomyosarcoma, Nasopharyngeal cancer, Neuroendocrine tumours, Osteosarcoma, Peripheral T-cell lymphoma, Peritoneal cancer, Prostate cancer, Recurrent respiratory papillomatosis, Small cell lung cancer, Solid tumours, Squamous cell cancer, Thymoma, Liposarcoma, Lymphoma, Oropharyngeal cancer, Pancreatic cancer, Acute myeloid leukaemia, Follicular lymphoma, Hodgkin's disease, Liver cancer, Meningioma, Bone metastases, Anal cancer, Cervical cancer, Vulvovaginal cancer, Meningioma
Conditions Discontinuedna
NotesAvelumab and Bintrafusp have identical V domains

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy